New pill could regrow hair in balding autoimmune disease

NCT ID NCT06104839

Recruiting now Disease control Sponsor: NEXTGEN Bioscience Source: ClinicalTrials.gov ↗

First seen Apr 22, 2026 · Last updated May 20, 2026 · Updated 5 times

Summary

This study tests a new drug called NXC736 for people with moderate to severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 73 adults aged 19 to 65 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug safely helps regrow hair, measured by a standard hair loss score.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Kyung Hee University Hospital at Gangdong
RECRUITING

Seoul, 05278, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••
Seoul National University Hospital.
RECRUITING

Seoul, 03080, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ALOPECIA AREATA